About IMI
IMI in a nutshell

Key achievements

- 11 years 113 projects
- 5.3 bn budget
- >7000 project outputs (such as biomarkers and cell lines)
- >3800 scientific publications
- >900 participating entities from 42 countries
IMI2 funding
(2014-2020)

€ 3.276 bn
TOTAL IMI2 BUDGET

IN-KIND PRIVATE CONTRIBUTION
€1.425 bn
EFPIA companies receive no funding

PUBLIC CONTRIBUTION
€1.638 bn
funding from Horizon 2020

EU funding goes to:

- SMES
- UNIVERSITIES
- PATIENTS, REGULATORS...

OTHER CONTRIBUTIONS
€213 MILLION
(Associated Partners, e.g., charities, non-EFPIA companies)

EFPIA contribute researchers, laboratories, generation of data, curation of compounds, and cash

Public and private partners collaborate in IMI2 projects

Accelerating research and development

Speeding up patient access to innovative treatments

Improving patient outcomes and safety of medicines
Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises (≤ €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:
- EU Member State
- Associated Country

Other countries: No funding unless participation deemed essential by IMI2 JU for carrying out the action

Art.1 Commission Delegated Regulation (EU) No 622/2014
How IMI Call topics are generated

1/3

Drafted in consultation with the scientific community

All subsequent versions done in consultation with IMI Scientific Committee

IMI2 STRATEGIC RESEARCH AGENDA (2014-2020)

World Health Organisation Priority Medicines for Europe and the world

EU health research priorities

Major challenges for the pharmaceutical industry
How IMI Call topics are generated

2/3

Proposals from the scientific community submitted via the IMI website

IMI'S ANNUAL RESEARCH PRIORITIES (PART OF IMI’S ANNUAL WORK PLAN)

IMI’s Strategic Governing Groups

IDENTIFICATION OF TOPICS

DRAFT TOPIC TEXT

Consultation with the IMI Scientific Committee and States Representatives Group
How IMI Call topics are generated

IMI STATES REPRESENTATIVES GROUP → CONSULTATION → IMI SCIENTIFIC COMMITTEE → IMI GOVERNING BOARD APPROVAL OF CALL DOCUMENTS → CALL LAUNCH
IMI’s standard Call process

- Topic definition
  - Industry
- Call launch!
  - Short proposal
  - Academics
  - Hospitals
  - Mid-size enterprises
  - Regulators
  - SMEs
  - Patients’ organisations
- Full proposal
  - Full consortium (industry + applicants)
- Grant Preparation

Evaluation

Join / form a consortium & apply for funding!

Project launch!
A single set of evaluation criteria

- Two-stage evaluation: all three criteria considered at both stages
- Thresholds and weighting in the Call documents depending two-stages/single stage
- Minimum of 3 independent experts

Each proposal evaluated ‘as it is’, not as ‘what could be’.
Funding per research area

- Drug discovery: €214,201,208
- Cancer: €142,051,549
- Inflammatory disorders: €80,494,654
- Infectious diseases: €1,101,524,489
- Data and knowledge management: €126,007,170
- Diabetes/metabolic disorder: €242,189,095
- Translational safety: €194,597,376
- Brain disorders: €304,044,515
IMI2 – Call 18 and 19 – indicative topics

Scheduled launch date: 26 June 2019

Topics Call 18:

- Central repository of digital pathology slides
- Health Outcomes Observatories – empower patients with tools to measure their outcomes in a standardised manner
- E-Health information: improving patient access, understanding and adherence to healthcare information:
- Establishing quality of life endpoints in oncology
- Accelerating research & development for advanced therapy medicinal products
- Supporting the development of chimeric antigen receptor T cells

Call 19. restricted call to maximise impact of IMI2 JU objectives and scientific priorities

More info: bit.ly/FutureTopics
## Topics in the long term pipeline

<table>
<thead>
<tr>
<th>What?</th>
<th>Titles &amp; short summaries for long-term future Calls (i.e. several months away)</th>
</tr>
</thead>
</table>
| Why? | - give potential applicants a glimpse into what is under development in the longer term  
    - provide additional time to enhance networks |
| Important note! | Discussions on these topics are still in their early stages. They are likely to change considerably. Some topics may be dropped (but new ones may be added to the list). |

All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.
The IMI community

- 597 Universities/Academic organisations
- 33 patients groups
- 229 SMES
- 61 EFPIA members
- 23 EFPIA partners in research
- 29 Regulators
- 27 Associated Partners

Connecting great minds
What does an IMI project look like?

53 organisations from 11 countries, working across 7 hematological malignancies
Stakeholder Forum 2019 “Brain health and disease in the digital era - 2020 & beyond”

Wednesday 12 June at Royal Museum of Fine Arts of Belgium

Built around 4 sessions following the patient’s path from prevention to care

- **Brain Health and prevention:** how do stakeholders engage with digital health technologies; reliability and performance while assuring legal, regulatory & ethical compliance
- **Diagnosis:** explore the potential of digital technologies to facilitate timely and accurate diagnosis.
- **Treatment:** what is needed for digital technologies to become part of the treatment possibilities for brain disorders
- **Care:** usability, usefulness, and acceptance of digital health technologies by the patients and their carers.
Your contact points

At the IMI Programme Office
- General queries: applicants@imi.europa.eu
- IP queries: IMI-IP-Helpdesk@imi.europa.eu

Local contacts
- IMI2 JU States Representatives Group: bit.ly/IMISRG
- Horizon 2020 Health National Contact Points: bit.ly/H2020_NCPs